Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
EClinicalMedicine. 2024 Mar 27:71:102564.
doi: 10.1016/j.eclinm.2024.102564.
eCollection 2024 May.
1 Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.
2 Massachusetts General Hospital, USA.
3 Newcastle University Centre for Cancer, UK.
4 Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.
5 Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.
6 Alfred Health, Australia.
7 Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
8 The Christie NHS Foundation Trust, Manchester, UK.
9 Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.
10 University of Perugia, Italy.
11 Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
12 Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
13 Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
14 Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
15 Department of Dermatology, University Medical Center Hamburg-Eppendorf (UKE), University Skin Cancer Center, Hamburg, Germany.
16 Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
17 Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney, North Sydney, NSW, Australia.
18 Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
19 UPMC Hillman Cancer Center, Pittsburgh, PA, USA.